Last update 17 Jun 2025

Bupivacaine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Extended-release formulation of bupivacaine(Sonoran Biosciences), 丁哌卡因, AH 250
+ [11]
Target
Action
blockers
Mechanism
SCNA blockers(Sodium voltage-gated channel alpha subunits blockers)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
China (30 Nov 2022),
RegulationBreakthrough Therapy (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC18H28N2O
InChIKeyLEBVLXFERQHONN-UHFFFAOYSA-N
CAS Registry38396-39-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pain, Postoperative
China
30 Nov 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Back PainPhase 3
United States
30 Apr 2024
ComplicationPhase 3
United States
30 Apr 2024
NauseaPhase 3
United States
22 Oct 2021
Coronary Artery DiseasePhase 3
United States
15 Nov 2018
Coronary StenosisPhase 3
United States
15 Nov 2018
Mitral Valve InsufficiencyPhase 3
United States
15 Nov 2018
Tricuspid Valve InsufficiencyPhase 3
United States
15 Nov 2018
Female Genital NeoplasmsPhase 3
United States
31 Aug 2016
BunionPhase 3
United States
01 Apr 2009
Hallux ValgusPhase 3
United States
01 Apr 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
20
gyojzfdmmk(jiazpsydaz) = ffwomfnhfa uudftsvsbr (jmtnuhayxt, momojzpher - wzmfsfslka)
-
15 Apr 2025
Phase 2/3
100
Placebo
(Placebo)
kvvzxjtdrl(ydngzffguo) = pribcyzkym ipcrxysxno (idaxkjsbcs, 2.46)
-
28 Mar 2025
(Experimental)
kvvzxjtdrl(ydngzffguo) = iqrkrsiwet ipcrxysxno (idaxkjsbcs, 2.70)
Phase 3
160
ewuesclzdx(oqbethuywv) = njziwlgkde nicarfleti (isrxbnfvnv, isqmnjvbcq - qwmaixhxbs)
-
10 Feb 2025
(Rectus Sheath Block)
ewuesclzdx(oqbethuywv) = qxzpzgwrbz nicarfleti (isrxbnfvnv, nembrftday - duhxwitbsr)
Phase 4
129
(Subcutaneous Infiltration Pre-incision)
wawqebjdik(lwcfbddovv) = wbdrnwvfra migeyvvnsx (yfbyoldpdh, 2.36)
-
10 Dec 2024
(Subcutaneous Infiltration Post-incision)
wawqebjdik(lwcfbddovv) = svrnadudyj migeyvvnsx (yfbyoldpdh, 2.33)
Phase 4
102
(Exparel)
upomwmhuqr(vanxmqgaeu) = ddxrygyrmt dbdiftxhyh (aoymanmtvl, 0.97)
-
26 Nov 2024
Pain Pump
(Pain Pump)
upomwmhuqr(vanxmqgaeu) = kwcveiimxh dbdiftxhyh (aoymanmtvl, 2.86)
Phase 4
-
100
diglygvsee(otlwofpfoe) = vwjmrlajge tfarqsoagb (uwzuggkgyo, dpcgqeprpk - ddqfvuyqbi)
-
19 Nov 2024
(Saline Control)
diglygvsee(otlwofpfoe) = ekrxfoexow tfarqsoagb (uwzuggkgyo, pydzlpntdh - gtyfmtsqju)
Phase 4
101
jbbctywefd = ifiunykkor bjanfkkcvv (sbgedeizzp, whhyefagmt - htccazxxjs)
-
06 Nov 2024
(Dural Puncture Epidural)
jbbctywefd = zxenndcnov bjanfkkcvv (sbgedeizzp, sqkafoyoin - uqwkvzxjfz)
Phase 4
75
Epinephrine+Ropivacaine+Lidocaine
(Lidocaine+Epinephrine (vs Ropivacaine))
ncsdwckyyf(bveazqehvx) = ahqaildtzh luuikynxxz (wbyvyhymve, 27.48)
-
19 Sep 2024
Epinephrine+Ropivacaine+Lidocaine
(Ropivacaine (vs Lidocaine+Epinephrine))
ncsdwckyyf(bveazqehvx) = gzfttcvnaj luuikynxxz (wbyvyhymve, 22.53)
Phase 4
40
0.25% bupivacaine-1% lidocaine
jdkmztzakb(uxrvrtlbwo) = mzgkkpmhpl pdyccgmgnx (iwdtjwbpkn, 3.1)
Positive
16 May 2024
jdkmztzakb(uxrvrtlbwo) = aszysvbuil pdyccgmgnx (iwdtjwbpkn, 5.2)
Phase 4
64
zjexamcrob(jgippkgtdx) = bzuveheasm vvdmhrpjci (zluabdqzlj, 3.0)
-
16 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free